从研发到产业落地 贝捷迈 ® 申报受理助力和誉医药进阶

中国工业新闻网
Jan 14

贝捷迈®由和誉医药自主研发,并授权默克公司负责其在全球的商业化。2025年12月,贝捷迈®获中国国家药品监督管理局(NMPA)批准上市,用于手术切除可能会导致功能受限或出现较严重并发症的症状性TGCT成年患者。目前,该产品在其他市场的上市申请正由相关监管机构审评中。此次贝捷迈®NDA获FDA受理,主要基于全球多中心、随机、双盲、安慰剂对照III期MANEUVER研究的积极结果。研究显示,每日一次...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10